Hims & Hers is spending hundreds of millions to build out its own physical infrastructure, including a million square feet of pharmacy fulfillment and acquiring diagnostics companies like YourBio Health. This strategy aims to control the entire patient journey, from testing to treatment delivery.
The company made a major international push by acquiring Eucalyptus for approximately $1.5B, gaining a dominant position in Australia, the UK, and Germany. This signals a clear intent to build a global brand rather than remaining a US-centric player.
Hims & Hers is fundamentally altering the pharmaceutical distribution model by dramatically reducing cash-pay prices for high-demand drugs, such as cutting GLP-1 costs by over 80%. The company also partners with preventative care providers like Grail and Prenuvo to make advanced screenings more accessible.
CEO Andrew Dudum deliberately hires leaders who have proven resilience by navigating high-pressure crises (e.g., at Uber during COVID, Robinhood during GameStop). He actively avoids the common founder mistake of hiring 'strategic' executives from large corporations, preferring hands-on builders.
The company is actively implementing AI to achieve significant efficiency gains, citing a 3-4x increase in design team output without increasing headcount. Dudum sees massive potential in applying AI to electronic medical records to improve clinical outcomes and efficiency.
Keep pulling the thread on Andrew Dudum.